Life Epigenetics

Life Epigenetics was a private U.S. epigenetics company focused on commercializing DNA methylation-based biomarker technology to estimate biological age, mortality risk, and longevity-related health measures. The company emerged as an insurtech and health-technology venture tied to GWG Holdings and held an exclusive license to mortality-predictive epigenetic technology developed from Steve Horvath's work at UCLA. Its offerings centered on epigenetic testing, methylation analysis, and biomarker-driven analytics for applications spanning life insurance underwriting, longevity, wellness, and broader health assessment. Corporate records indicate the original Life Epigenetics entity was later folded into the FOXO corporate structure and renamed FOXO Labs, while third-party databases currently describe the Life Epigenetics brand/entity itself as closed. The company was not a therapeutic drug developer and did not appear to run a conventional drug pipeline.